45 Pont Street
23 articles with Ixaka
Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power of the body to cure disease, announces the appointment of Dr Karen Miller as Chief Scientific Officer.
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
Ixaka Ltd, an integrated cell and gene therapy company, announces that Advanced Therapy Medicinal Product classification has been granted by the European Medicines Agency for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy targeted nanoparticle product.
Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces the appointment of Nick Robbins-Cherry as Chief Financial Officer and board Director, and George O’Rourke as Vice President and General Manager of Ixaka France.
Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001
Ixaka Ltd, an integrated cell and gene therapy company, announces positive interim results of its lead REX-001 drug candidate from a Phase 3 clinical trial, which evaluated the safety and efficacy results 12 months after treatment with REX-001 or placebo in patients diagnosed with chronic limb-threatening ischemia and diabetes.
Ixaka Ltd and SomaLogic announce a research collaboration to support the development of aptamer-based bispecific therapeutics.
Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.
Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces that Christian Hoyer Millar has joined the Company’s Board as a Non-Executive Director.
Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia, announces the appointment of Sadia L’Baouch as Chief Manufacturing Officer, effective 4 January 2021.
Rexgenero Announces Positive Outcome of Independent Data Monitoring Committee Meeting for Phase III Trial for Diabetic Patients with Critical Limb-Threatening Ischaemia
REX-001 is an autologous cell-based product intended to treat critical limb-threatening ischaemia in diabetic patients
Rexgenero announces that Dr Gilbert Wagener has joined the Company as Senior Vice President and Chief Medical Officer.
Rexgenero announces that Dr Huw Jones has joined the Company’s Board as a non-executive director, and will chair the Company’s remuneration committee.
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia, announces that Dr. David Horn Solomon has been appointed to the role of Chairman, effective immediately.
8/22/2019Companies from across the globe provide updates on their business and pipelines.
Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.
First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava
Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting
Rexgenero Successfully Expands Manufacturing of REX-001 through Partnership with German Red Cross Blood Donor Service
Enables new sites to participate in the European Phase III SALAMANDER trials
Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia
At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona
EMA Grants Rexgenero's Lead Product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data
The EMA certification paves the way for the MAA of its lead product REX-001, a novel cell therapy currently in a Phase III programme for the treatment of CLI.
The grant is a consortium between the Cell and Gene Therapy Catapult, TrakCel and Fisher Bioservices.